Exploring the Knowledge, Attitudes, Behaviors and Perceived Barriers of Hepatologists Towards Non-invasive Hepatocellular Carcinoma Prediction Models in Hepatitis C Patients Who Achieved Sustained Virological Response Following Direct Acting Antivirals Therapy

Launched by ASSIUT UNIVERSITY · Mar 7, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how well hepatologists, who are doctors specializing in liver diseases, understand and use different tools to predict the risk of liver cancer, specifically hepatocellular carcinoma (HCC), in patients with chronic hepatitis C who have successfully responded to treatment. The goal is to find out how knowledgeable these doctors are about these prediction models, how confident they feel using them, and what challenges they face when trying to incorporate these tools into their practice. The study will gather this information through a questionnaire sent to hepatologists around the world.

To participate in this study, doctors must have at least one year of experience treating hepatitis C patients. The trial is not yet recruiting participants, but when it does, it will focus on getting insights from hepatologists about their experiences and attitudes towards these predictive models. This information could help improve the way liver cancer risks are assessed and managed in patients who have undergone hepatitis C treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Hepatologists with at least one year of experience in managing HCV patients
• Exclusion Criteria:
• • Non-hepatologists, general practitioners, or respondents who submit incomplete surveys